These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 31090280

  • 1. Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
    Citrome LL, McIntyre RS, Manning JS, McIntosh D.
    J Clin Psychiatry; 2019 Apr 30; 80(3):. PubMed ID: 31090280
    [Abstract] [Full Text] [Related]

  • 2. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
    Seetasith A, Greene M, Hartry A, Burudpakdee C.
    J Med Econ; 2018 Sep 30; 21(9):888-901. PubMed ID: 29862860
    [Abstract] [Full Text] [Related]

  • 3. Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
    Fava M, Okame T, Matsushima Y, Perry P, Weiller E, Baker RA.
    Int J Neuropsychopharmacol; 2017 Jan 01; 20(1):22-30. PubMed ID: 27784751
    [Abstract] [Full Text] [Related]

  • 4. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH, Thase ME, Fava M, Nelson CJ, Yang H, Qi Y, Tran QV, Pikalov A, Carlson BX, Marcus RN, Berman RM.
    J Clin Psychiatry; 2008 Dec 01; 69(12):1928-36. PubMed ID: 19192475
    [Abstract] [Full Text] [Related]

  • 5. The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.
    Bartova L, Fugger G, Dold M, Kautzky A, Swoboda MMM, Rujescu D, Zohar J, Souery D, Mendlewicz J, Montgomery S, Fabbri C, Serretti A, Kasper S.
    Int J Neuropsychopharmacol; 2022 Feb 11; 25(2):118-127. PubMed ID: 34637516
    [Abstract] [Full Text] [Related]

  • 6. Activating and Tranquilizing Effects of First-Time Treatment with Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Youth.
    Al-Dhaher Z, Kapoor S, Saito E, Krakower S, David L, Ake T, Kane JM, Correll CU, Carbon M.
    J Child Adolesc Psychopharmacol; 2016 Jun 11; 26(5):458-70. PubMed ID: 27093218
    [Abstract] [Full Text] [Related]

  • 7. Second-Generation Antipsychotic-Induced Hypoglycemia.
    Fujita T, Mizoguchi Y, Kunitake Y, Tateishi H, Inaba T, Kato TA, Monji A.
    Prim Care Companion CNS Disord; 2018 Jan 25; 20(1):. PubMed ID: 29372938
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C, Papakostas GI, Jing Y, Baker RA, Forbes RA, Oster G.
    Ann Pharmacother; 2012 May 25; 46(5):642-9. PubMed ID: 22550279
    [Abstract] [Full Text] [Related]

  • 9. Aripiprazole in refractory depression?
    Carroll BJ.
    J Clin Psychopharmacol; 2009 Feb 25; 29(1):90-1; author reply 92-3. PubMed ID: 19142117
    [No Abstract] [Full Text] [Related]

  • 10. The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
    Citrome L.
    Int J Clin Pract; 2015 Nov 25; 69(11):1211-20. PubMed ID: 26477545
    [No Abstract] [Full Text] [Related]

  • 11. Second-generation antipsychotics for major depressive disorder and dysthymia.
    Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S.
    Cochrane Database Syst Rev; 2010 Dec 08; (12):CD008121. PubMed ID: 21154393
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
    Sussman M, Yu J, Kamat SA, Hartry A, Legacy S, Duffy R, Aigbogun MS.
    J Affect Disord; 2017 Jan 01; 207():54-62. PubMed ID: 27693466
    [Abstract] [Full Text] [Related]

  • 13. Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.
    Tsai AC.
    J Clin Psychopharmacol; 2009 Feb 01; 29(1):91-2; author reply 92-3. PubMed ID: 19142118
    [No Abstract] [Full Text] [Related]

  • 14. Adjunctive antipsychotics for major depression.
    Med Lett Drugs Ther; 2011 Sep 19; 53(1373):74-5. PubMed ID: 21921872
    [No Abstract] [Full Text] [Related]

  • 15. Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects.
    DeBattista C, DeBattista K.
    Curr Drug Saf; 2010 Jul 02; 5(3):263-6. PubMed ID: 20394571
    [Abstract] [Full Text] [Related]

  • 16. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
    Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I.
    Clin Ther; 2019 Feb 02; 41(2):221-232. PubMed ID: 30616973
    [Abstract] [Full Text] [Related]

  • 17. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH, Lin SH, Jang FL.
    J Clin Psychopharmacol; 2011 Oct 02; 31(5):563-8. PubMed ID: 21869699
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.